These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38811946)

  • 1. HF Etiology and cardiac contractility modulation therapy.
    Davtyan K; Chugunov I; Topchyan A; Mareev Y; Mironova N; Rimskaya E; Golitsyn S; Mikhaylov E; Lebedev D; Vander M; Lyasnikova E; Sitnikova M; Minjia K; Glembo S; Sukhorukov O
    BMC Cardiovasc Disord; 2024 May; 24(1):279. PubMed ID: 38811946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cardiac contractility modulation on left ventricular global and regional function and remodeling.
    Yu CM; Chan JY; Zhang Q; Yip GW; Lam YY; Chan A; Burkhoff D; Lee PW; Fung JW
    JACC Cardiovasc Imaging; 2009 Dec; 2(12):1341-9. PubMed ID: 20083066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of left atrial appendage closure in atrial fibrillation patients with different types of heart failure.
    Liu L; Yan W; Xu X; Wan C; Liu F; Yao Q; Song L; Wang B; Song Z; Li H
    BMC Cardiovasc Disord; 2024 Aug; 24(1):430. PubMed ID: 39148039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac Contractility Modulation in Patients with Ischemic versus Non-ischemic Cardiomyopathy: Results from the MAINTAINED Observational Study.
    Fastner C; Yuecel G; Rudic B; Schmiel G; Toepel M; Burkhoff D; Liebe V; Kruska M; Hetjens S; Borggrefe M; Akin I; Kuschyk J
    Int J Cardiol; 2021 Nov; 342():49-55. PubMed ID: 34329680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac contractility modulation: first experience in heart failure patients with reduced ejection fraction and permanent atrial fibrillation.
    Röger S; Schneider R; Rudic B; Liebe V; Stach K; Schimpf R; Borggrefe M; Kuschyk J
    Europace; 2014 Aug; 16(8):1205-9. PubMed ID: 24706089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of β-blocker therapy on right ventricular function in heart failure patients with reduced ejection fraction. A prospective evaluation.
    Galves R; Da Costa A; Pierrard R; Bayard G; Guichard JB; Isaaz K
    Echocardiography; 2020 Sep; 37(9):1392-1398. PubMed ID: 32815195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for Exercise Tolerance and Outcomes.
    Nadruz W; West E; Santos M; Skali H; Groarke JD; Forman DE; Shah AM
    Circ Heart Fail; 2016 Apr; 9(4):e002826. PubMed ID: 27009553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal evaluation of ventricular ejection fraction and NT-proBNP across heart failure subgroups.
    Martinsson A; Oest P; Wiborg MB; Reitan Ö; Smith JG
    Scand Cardiovasc J; 2018 Aug; 52(4):205-210. PubMed ID: 29656687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profound differences in prognostic impact of left ventricular reverse remodeling after cardiac resynchronization therapy relate to heart failure etiology.
    Martens P; Nijst P; Verbrugge FH; Dupont M; Tang WHW; Mullens W
    Heart Rhythm; 2018 Jan; 15(1):130-136. PubMed ID: 28843420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results of combined cardiac contractility modulation and subcutaneous defibrillator therapy in patients with heart failure and reduced ejection fraction.
    Röger S; Rudic B; Akin I; Shchetynska-Marinova T; Fastenrath F; Tülümen E; Liebe V; El-Battrawy I; Baumann S; Kuschyk J; Borggrefe M
    Clin Cardiol; 2018 Apr; 41(4):518-524. PubMed ID: 29697870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Performance, and Efficacy of Cardiac Contractility Modulation Delivered by the 2-Lead Optimizer Smart System: The FIX-HF-5C2 Study.
    Wiegn P; Chan R; Jost C; Saville BR; Parise H; Prutchi D; Carson PE; Stagg A; Goldsmith RL; Burkhoff D
    Circ Heart Fail; 2020 Apr; 13(4):e006512. PubMed ID: 32264716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should HFrEF patients with NYHA class II expect benefit from CCM therapy? Results from the MAINTAINED observational study.
    Fastner C; Yuecel G; Hetjens S; Rudic B; Schmiel G; Toepel M; Liebe V; Kruska M; Borggrefe M; Burkhoff D; Akin I; Duerschmied D; Kuschyk J
    Clin Res Cardiol; 2022 Nov; 111(11):1286-1294. PubMed ID: 36056955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized comparison of 5 versus 12 hours per day of cardiac contractility modulation treatment for heart failure patients: A preliminary report.
    Kloppe A; Mijic D; Schiedat F; Bogossian H; Mügge A; Rousso B; Lemke B
    Cardiol J; 2016; 23(1):114-9. PubMed ID: 26503077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of long-term survival by cardiac contractility modulation in heart failure patients: A case-control study.
    Liu M; Fang F; Luo XX; Shlomo BH; Burkhoff D; Chan JY; Chan CP; Cheung L; Rousso B; Gutterman D; Yu CM
    Int J Cardiol; 2016 Mar; 206():122-6. PubMed ID: 26788686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effects of long-term cardiac contractility modulation (CCM) in subjects with heart failure caused by left ventricular systolic dysfunction.
    Müller D; Remppis A; Schauerte P; Schmidt-Schweda S; Burkhoff D; Rousso B; Gutterman D; Senges J; Hindricks G; Kuck KH
    Clin Res Cardiol; 2017 Nov; 106(11):893-904. PubMed ID: 28685207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
    Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
    [No Abstract]   [Full Text] [Related]  

  • 17. Non-pharmacologic autonomic neuromodulation for treatment of heart failure: A systematic review and meta-analysis of randomized controlled trials.
    Ahmed M; Nudy M; Bussa R; Weigel F; Naccarelli G; Maheshwari A
    Trends Cardiovasc Med; 2024 Feb; 34(2):101-107. PubMed ID: 36202286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-Year Outcome of Cardiac Contractility Modulation in Patients With Reduced Ejection Fraction, Atrial Fibrillation, and Previous Resynchronization: A Pilot Study.
    Tint D; Micu S
    Am J Ther; 2023 Jan-Feb 01; 30(1):e10-e16. PubMed ID: 36367992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar predictive value of six-minute walking distance and B-type natriuretic peptide in heart failure with reduced to mid-range ejection fraction.
    Scardovi AB; De Maria R; Galeotti GG; Faggiano P; Arcari L; Ghio S; Temporelli PL; Rossi A; Magni G; Simioniuc A; Ricci R; Dini FL
    Monaldi Arch Chest Dis; 2019 Jul; 89(2):. PubMed ID: 31315349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial perfusion, function, and dyssynchrony in patients with heart failure: baseline results from the single-photon emission computed tomography imaging ancillary study of the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) Trial.
    Atchley AE; Kitzman DW; Whellan DJ; Iskandrian AE; Ellis SJ; Pagnanelli RA; Kao A; Abdul-Nour K; O'Connor CM; Ewald G; Kraus WE; Borges-Neto S;
    Am Heart J; 2009 Oct; 158(4 Suppl):S53-63. PubMed ID: 19782789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.